Azouaou Leila, Adnane Mounir, Chabati Omar, Arab Medina, Chahine Toualbi, Chader Henni
Nephrology Service, Hussein Dey Hospital, Algiers, Algeria.
Laboratory of Oxidative Stress, Kidney and Associated Complications, University of Algiers, Algeria.
Arch Med Sci Atheroscler Dis. 2024 Oct 15;9:e183-e192. doi: 10.5114/amsad/192427. eCollection 2024.
Cardiovascular diseases are common complications in chronic kidney disease (CKD). Oxidative stress associated with renal and metabolic dysfunctions is one of the cardiovascular complications (CVC) in haemodialysis patients. The aim of the present study is to analyse the oxidative stress markers in CDK patients supplemented with antioxidants and vitamin E, with monitoring of CVC.
This was a cross-sectional study conducted on 99 subjects. CKD patients received oral supplementation of vitamin E (300 mg/day) for 2 years. Oxidative stress markers, nitric oxide (NO); myeloperoxidase (MPO); oxidized low-density lipoprotein (LDLox); malondialdehyde (MDA) and glutathione were measured before and after the vitamin treatment.
NO (62.62 ±2.80 μmol/l), LDLox (10.55 ±4.62 μmol/l), MDA (6.11 ±2.83 μmol/l) and MPO (53.35 ±3.82 UI/ml) were overconcentrated, while glutathione (62.09 ±4.15 UI/ml) was less concentrated in CKD patients with cardiovascular complications, compared to those without cardiovascular complications (67.08 ±1.90 μmol/l, 31.18 ±5.25 μmol/l, 16 ±6.47 μmol/l, 57.00 ±7.24 UI/ml, 43.09 ±3.33 UI/ml, respectively). After 2 years of vitamin E treatment, the overall cardiovascular complications were not significantly decreased.
These results showed that oral complementation with vitamin E did not affect the occurrence of cardiovascular complications associated with CKD. These findings may pave the way for future innovative strategies for antioxidant supplementation in CKD patients.
心血管疾病是慢性肾脏病(CKD)常见的并发症。与肾脏和代谢功能障碍相关的氧化应激是血液透析患者心血管并发症(CVC)之一。本研究旨在分析补充抗氧化剂和维生素E的CKD患者的氧化应激标志物,并监测CVC。
这是一项对99名受试者进行的横断面研究。CKD患者口服补充维生素E(300毫克/天),持续2年。在维生素治疗前后测量氧化应激标志物,包括一氧化氮(NO)、髓过氧化物酶(MPO)、氧化型低密度脂蛋白(LDLox)、丙二醛(MDA)和谷胱甘肽。
与无心血管并发症的CKD患者相比(分别为67.08±1.90微摩尔/升、31.18±5.25微摩尔/升、16±6.47微摩尔/升、57.00±7.24国际单位/毫升、43.09±3.33国际单位/毫升),有心血管并发症的CKD患者中,NO(62.62±2.80微摩尔/升)、LDLox(10.55±4.62微摩尔/升)、MDA(6.11±2.83微摩尔/升)和MPO(53.35±3.82国际单位/毫升)浓度过高,而谷胱甘肽(62.09±4.15国际单位/毫升)浓度较低。维生素E治疗2年后,总体心血管并发症并未显著减少。
这些结果表明,口服补充维生素E不会影响与CKD相关的心血管并发症的发生。这些发现可能为未来CKD患者抗氧化剂补充的创新策略铺平道路。